Before anyone gets too excited, it is only to do with some...

Before anyone gets too excited, it is only to do with some global malaria-based press that is being linked to, from within the EMS website, but the fact that someone is bothering to maintain the website (see the malaria in the news box) is not a bad sign.

http://www.voanews.com/content/experts-say-poor-quality-drugs-hamper-malaria-fight/1120711.html

http://www.copcap.com/content/us/quick_links/news/latest_news/2012/news_2nd_quarter_2012/danish_scientists_reveal_lethal_gene_in_malaria.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037927;jsessionid=CB408FABA198247B2D5C755708ABA461

Having said that, their clinical trials page (under the product/arTiMist tab refers to PhIII completion being this finacial year (which is probably a bit ambitious given that there is only 30 days left - it may have even been posted in the previous financial year. Further the pipeline page, under the same tab doesn't indicate that we are even in PhIII trails.

So maybe they aren't as vigilent as I first thought.

Bring on completion of PhIII trials and registration of the drug for substantial derisking of this stock

bluebush


bluebush